Compare ONTO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTO | NBIX |
|---|---|---|
| Founded | 1940 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 15.5B |
| IPO Year | 1995 | 1996 |
| Metric | ONTO | NBIX |
|---|---|---|
| Price | $287.58 | $138.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $290.63 | $180.91 |
| AVG Volume (30 Days) | 744.2K | ★ 985.4K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.88 | ★ 3.30 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $26.63 | $24.73 |
| Revenue Next Year | $16.26 | $13.14 |
| P/E Ratio | $148.79 | ★ $42.10 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $118.97 | $122.14 |
| 52 Week High | $386.46 | $186.12 |
| Indicator | ONTO | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 25.64 |
| Support Level | $267.11 | $125.85 |
| Resistance Level | $288.63 | $138.74 |
| Average True Range (ATR) | 11.06 | 3.91 |
| MACD | 3.83 | -1.32 |
| Stochastic Oscillator | 95.04 | 6.56 |
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.